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Abstract: A new generation of sepsis therapeutics is in devel-
opment to promote clearance of microbial pathogens or their
mediators and regulate the deleterious elements of the systemic
host response in sepsis/septic shock. These investigations are
undertaken with the realization that prior efforts to improve out-
comes in sepsis have ﬂawed either by: (1) failing to account for
the intrinsic complexity of sepsis pathophysiology; or (2) assum-
ing that septic patients would respond in a uniform and predicable
manner to the experimental therapy. Clearly the deﬁnition for
sepsis as an infection with systemic inﬂammatory response syn-
drome does not deﬁne a patient population that consistently and
predictably reproduces the same outcome with novel sepsis ther-
apeutics. The current sepsis treatments in clinical development
are targeting a speciﬁc subpopulation of septic patients likely to
respond to the invention. They studies generally rely upon some
type of laboratory biomarker to predict with greater accuracy the
likelihoodof responsiveness to the speciﬁc therapeutic agent under
evaluation.
Novel therapeutics now under clinical evaluation are targeting
oneof the following: thepathogenormicrobialmediators (hemoﬁl-
ters); epithelial barrier support strategies (protease inhibitors,
growth factors); endothelial barrier protectors (angiopoietin-1/Tie
2, anti-complement antibodies, thrombomodulin, etc.); immune
reconstitutionagents (anti PDL1antibody, thymosin-1,GM-CSF), or
other targets (gelsolin, pro-protein convertases, HMGB-1 antibod-
ies, and pro-resolving agents). In this era of precision medicine it is
now possible to deﬁne a responsive patient population to a speciﬁc
agent with much better accuracy. This biomarker-based strategy
is now being put to the test in current clinical trials in sepsis with
new therapeutic agents.
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Abstract: Background: The Surveillance for Enteric Fever in
Asia Project (SEAP) is a phased multi-country, multi-site surveil-
lance study designed to characterize the burden of enteric fever in
selected settings in Bangladesh, Nepal, and Pakistan.
Objectives: SEAP Phase I is aimed to assess health facilities with
potential toparticipate inphase II, and to informthedesignof phase
II. SEAP Phase II objectives are to use the study sites identiﬁed in
phase 1 to characterize the burden of enteric fever in selected Asian
settings, including clinical manifestations, severity of illness, long-
termsequelaeof illness, antimicrobial resistancepatternsof enteric
fever isolates, and cost of illness.
Methods: SEAP Phase I was a 2-year retrospective review of
existing data. SEAP Phase II is a prospective study combining
hospital-based and laboratory surveillancewith healthcare utiliza-
tion survey to estimate disease burden. Phase II will also include
long-term follow-up of all blood culture conﬁrmed cases to assess
long-term sequelae, an economic evaluation to characterize the
economic burdenof enteric fever, and thedescriptionof the antimi-
crobial sensitivity proﬁle. All positive specimens collected will be
included in a bank of Salmonella bacterial strains isolated during
the study period.
Results of Phase I: In Bangladesh, Salmonella typhi and S. paraty-
phi accounted for 29% and 5% of all blood cultures in children
enrolled in the ongoing Invasive Bacterial Vaccine Preventable Dis-
eases Surveillance. Forty-ﬁve percent were female. Fever, diarrhea,
nausea/vomiting and abdominal pain were present in 100%, 30%,
29% and10%of patients, respectively. In Pakistan, 81% and29%of all
microbiologically-conﬁrmedenteric fever cases,were S. typhi and S.
paratyphi, respectively. Thirty-six percentwere female. Fever, diar-
rhea, nausea/vomiting and abdominal pain were present in 97%,
26%, 40% and 21% of patients, respectively.
Conclusion: Results of SEAP Phase I demonstrate the continued
burden of typhoid fever illness in participating countries, and high-
light the need for SEAP Phase II, a well-designed prospective study
based on input of committed stakeholders to better quantify true
burden of illness and severity. Ultimately, results of SEAP Phase II
will inform policy recommendations for vaccine use, and facilitate
the assessment of the impact of interventions.
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